Predictive Oncology (POAI) 10-Q 15 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 14, 2019
Document Information [Line Items]
Entity Registrant Name	Precision Therapeutics Inc.
Entity Central Index Key	0001446159
Trading Symbol	aipt
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding (in shares)		30,680,570
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current Assets:
Cash and Cash Equivalents	$ 1,124,730	$ 162,152
Accounts Receivable	173,443	232,602
Notes Receivable (inclusive of $738,138 and $452,775 in advances to Helomics)	1,801,479	497,276
Inventories	289,023	241,066
Prepaid Expense and other assets	265,584	318,431
Total Current Assets	3,654,259	1,451,527
Notes Receivable		1,112,524
Fixed Assets, net	148,709	180,453
Intangibles, net	950,049	964,495
Lease Right-of-Use Assets	333,944
Total Assets	5,086,961	3,708,999
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts Payable	432,198	445,689
Note Payable – Bridge Loan Net of Discount of $646,524 and $969,786	1,812,037	1,327,942
Notes Payable – Net of Discount of $352,961 and $63,028	1,267,039	306,972
Accrued Expenses	797,599	1,279,114
Derivative Liability	353,210	272,745
Deferred Revenue	20,929	23,065
Current Lease Liability	78,819
Total Current Liabilities	4,761,831	3,655,527
Lease Liability	255,125
Total Liabilities	5,016,956	3,655,527
Stockholders’ Equity:
Common Stock, $.01 par value, 100,000,000 authorized, 17,360,144 and 14,091,748 outstanding	173,601	140,917
Additional paid-in capital	66,296,741	63,019,708
Accumulated Deficit	(66,401,129)	(63,107,945)
Total Stockholders' Equity	70,005	53,472
Total Liabilities and Stockholders' Equity	5,086,961	3,708,999
Series B Convertible Preferred Stock [Member]
Stockholders’ Equity:
Series B Convertible Preferred Stock, $.01 par value, 20,000,000 authorized, 79,246 and 79,246 outstanding	$ 792	$ 792

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Notes receivable	$ 1,801,479	$ 497,276
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares outstanding (in shares)	17,360,144	14,091,748
Series B Convertible Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares outstanding (in shares)	79,246	79,246
Bridge Loan [Member]
Discount of note payable	$ 646,524	$ 969,786
Notes Payable [Member]
Discount of note payable	352,961	63,028
Helomics Holding [Member]
Notes receivable	$ 738,138	$ 452,775

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue	$ 255,241	$ 411,593
Cost of goods sold	73,717	117,343
Gross margin	181,524	294,250
General and administrative expense	1,497,945	1,241,961
Operations expense	466,566	287,590
Sales and marketing expense	554,216	550,538
Total operating loss	2,337,203	1,785,839
Other income	53,432	27,655
Other expense	569,776	1,838
Loss on equity method investment	439,637
Net loss attributable to common shareholders	$ (3,293,184)	$ (1,760,022)
Loss per common share - basic and diluted (in dollars per share)	$ (0.21)	$ (0.15)
Weighted average shares used in computation - basic and diluted (in shares)	15,731,517	11,383,217

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Series E Warrants [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Series E Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Series E Warrants [Member]Preferred Stock [Member]	Series E Warrants [Member]Common Stock [Member]	Series E Warrants [Member]Additional Paid-in Capital [Member]	Series E Warrants [Member]Retained Earnings [Member]	Series E Warrants [Member]AOCI Attributable to Parent [Member]	Chief Executive Officer [Member]Preferred Stock [Member]Series C Preferred Stock [Member]	Chief Executive Officer [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Chief Executive Officer [Member]Preferred Stock [Member]	Chief Executive Officer [Member]Common Stock [Member]	Chief Executive Officer [Member]Additional Paid-in Capital [Member]	Chief Executive Officer [Member]Retained Earnings [Member]	Chief Executive Officer [Member]AOCI Attributable to Parent [Member]	Chief Executive Officer [Member]	Preferred Stock [Member]Series C Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2017																		$ 7,271	$ 69,432	$ 57,380,256	$ (54,765,045)		$ 2,691,913
Balance (in shares) at Dec. 31, 2017																647,819	79,246		6,943,283
Preferred conversion to common shares pursuant to private placement agreement																		(6,479)					(6,479)
Preferred conversion to common shares pursuant to private placement agreement (in shares)																(647,819)
Preferred conversion to common shares pursuant to private placement agreement (in shares)																			589,747
Preferred conversion to common shares pursuant to private placement agreement																			$ 5,897	582			0
Shares issued pursuant to the public offering																			$ 29,000	2,726,087			2,755,087
Shares issued (in shares)																			2,900,000
Investment pursuant to Helomics 20% acquisition																			$ 11,000	1,031,250			1,042,250
Investment pursuant to Helomics 20% acquisition (in shares)																			1,100,000
Warrant exercises				$ 558	$ 55,238
Warrant exercises (in shares)				55,796
Vesting Expense																				226,387			226,837
Net loss																					(1,760,022)		(1,760,022)
Balance at Mar. 31, 2018																		792	$ 118,040	61,622,067	(56,525,066)		5,215,833
Balance (in shares) at Mar. 31, 2018																	79,246		11,804,073
Balance at Dec. 31, 2018																		792	$ 140,917	63,019,708	(63,107,945)		53,472
Balance (in shares) at Dec. 31, 2018																	79,246		14,091,748
Preferred conversion to common shares pursuant to private placement agreement
Preferred conversion to common shares pursuant to private placement agreement (in shares)																			159,854
Preferred conversion to common shares pursuant to private placement agreement																			$ 1,599	88,401			90,000
Shares issued pursuant to the public offering											$ 781	$ 49,219			$ 50,000				$ 28,638	2,401,071			2,429,709
Shares issued (in shares)											78,125								2,863,750
Vesting Expense																				263,600			263,600
Net loss																					(3,293,184)		(3,293,184)
Shares issued in forbearance agreement																			$ 1,666	156,684			158,350
Shares issued in forbearance agreement (in shares)																			166,667
Warrants issued pursuant to CEO note payable																				318,058			318,058
Balance at Mar. 31, 2019																		$ 792	$ 173,601	$ 66,296,741	$ (66,401,129)		$ 70,005
Balance (in shares) at Mar. 31, 2019																	79,246		17,360,144

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flow from operating activities:
Net loss	$ (3,293,184)	$ (1,760,022)
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on equity method investment	439,637
Depreciation and amortization	39,526	18,167
Vesting expense for stock options	263,600	226,387
Amortization of debt discount	468,564
Loss on valuation of equity-linked instruments	19,408
Changes in assets and liabilities:
Accounts receivable	59,159	(104,265)
Inventories	(47,957)	(7,511)
Prepaid expense and other assets	(3,273)	81,661
Accounts payable	(13,491)	45,847
Accrued expenses	21,494	(226,775)
Deferred revenue	(2,136)	32,193
Net cash used in operating activities	(2,048,653)	(1,694,318)
Cash flow from investing activities:
Redemption of certificates of deposit		244,971
Advance on notes receivable	(631,316)	(42,524)
Purchase of fixed assets		(32,789)
Transfer of fixed assets to inventory	9,863
Acquisition of intangibles	(3,198)	(24,029)
Net cash (used in) provided by investing activities:	(624,651)	145,629
Cash flow from financing activities:
Extinguishment of convertible debt	(93,827)
Proceeds from debt issuance	1,250,000
Proceeds from exercise of warrants into common stock		55,794
Issuance of common stock	2,479,709	2,959,509
Net cash provided by financing activities	3,635,882	3,015,303
Net increase in cash and cash equivalents	962,578	1,466,614
Cash at beginning of period	162,152	766,189
Cash at end of period	1,124,730	2,232,803
Non-cash transactions:
Bridge loan conversion into common stock	90,000
Forbearance settlement bridge loan	503,009
Additional warrants issued pursuant to CEO note payable	8,665
Conversion of preferred stock to common stock		6,479
Equity method investment - Helomics		$ 1,542,250

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Continuance of Operations Precision Therapeutics Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of March 31, 2019, 17,360,144 $.01 two 1 2 April 2009, 510 The Company acquired 25% first 2018, April 2018 June 2018, April 4, 2019, 10. 149,000 first 2018, The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $66,401,129. not first no may The Company had cash and cash equivalents of $1,124,730 March 31, 2019 one not 3, $2.1 2019. may $5.0 Since inception to March 31, 2019, $38,970,000 $9,120,000 January 2018 $2,475,000; March 2019 $1,112,000 $1,053,000. September 2018 $1,815,000. November 2018, $370,000. February 2019, $950,000, March 2019 $300,000. Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Annual Report on Form 10 April 1, 2019. may not Recent Accounting Developments Accounting Policies and Estimates The presentation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. January 1, 2019, $353,007 $79,252 2016 02 not The Company leases facilities under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not See Note 8 Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1 Inventories Inventories are stated at the net realizable value, with cost determined on a first first March 31, December 31, Finished goods $ 88,849 $ 58,701 Raw materials 139,183 127,003 Work-In-Process 60,991 55,362 Total $ 289,023 $ 241,066 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3 The Company’s fixed assets consist of the following: March 31, December 31, Computers and office equipment $ 205,758 $ 204,903 Leasehold improvements 140,114 140,114 Manufacturing tooling 108,955 108,955 Demo equipment 74,529 85,246 Total 529,356 539,218 Less: Accumulated depreciation 380,647 358,765 Total Fixed Assets, Net $ 148,709 $ 180,453 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $21,882 three March 31, 2019 $14,496 three March 31, 2018. Intangible Assets Intangible assets consist of trademarks, patent costs and license fees. Amortization expense was $17,644 three March 31, 2019 $3,671 three March 31, 2018. The Company reviews identifiable intangible assets for impairment in accordance with ASC 360 Intangibles — Goodwill and Other , whenever events or changes in circumstances indicate the carrying amount may not may not not Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2015 Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one Segments The Company has two three March 31, 2019 Domestic International Totals Revenue $ 219,660 $ 35,581 $ 255,241 Segment Loss $ (887,831 ) $ (84,569 ) $ (972,400 ) Reconciliation of Segment Loss Description Amounts Domestic loss $ 887,831 International loss 84,569 Corporate losses 2,320,784 Total $ 3,293,184 Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not

Note 2 - Equity Method Investme

Note 2 - Equity Method Investment	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	NOTE 2 The Company has an equity method investment in Helomics. Summarized financial information for Helomics is presented below: Helomics Holdings Corporation For the three Months Ended March 31, 2019 Revenue $ 45,835 Gross margin $ 7,348 Net loss from continuing operations $ (1,555,542 ) Net loss to investee $ (1,166,656 ) 1 1 75% three

Note 3 - Revenue Recognition

Note 3 - Revenue Recognition	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	NOTE 3 Revenue from Product Sales The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases. The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses. Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of March 31, 2019, December 31, 2018, $173,443 $232,602, three March 31, 2019, not The Company deferred revenues related primarily to maintenance plans of $20,929 $23,065 March 31, 2019 December 31, 2018, Practical Expedients The Company has elected the practical expedient not

Note 4 - Stockholders' Equity (

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 4 2019 On March 1, 2019, 1,385,000 692,500 one 0.5 $1.00 $0.90 $1,246,608, 69,250 125% $1.125 February 27, 2024. On March 29, 2019, 1,478,750 739,377 one 0.5 $1.00 $0.80 $1,183,101, 73,937 125% $1.00 March 27, 2024. Increases in Authorized Shares At the annual meeting on December 28, 2017, 24,000,000 50,000,000 $0.01 January 2, 2018. At a special meeting of the stockholders on March 22, 2019, 50,000,000 100,000,000 $0.01 March 22, 2019. At a special meeting of the stockholders on March 22, 2019, 2012 10,000,000, Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Accounting for share-based payment The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the expected dividend rate, the risk-free interest rate, and forfeiture taken at occurrence. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. The Company has experienced no 2019, When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. For grants of stock option and warrants issued during the quarter ended March 31, 2019, 2.41% 2.76% 0% 79.8% 5 10 $0.4112 $.7644 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 1,098,858 1.01 2,336,154 1.07 Expired (194,564 ) 2.00 (10,706 ) 199.55 Exercised - - (650,062 ) 1.00 Outstanding at December 31, 2018 3,669,277 $ 1.70 3,626,643 $ 4.17 Issued 459,169 0.73 2,325,406 0.92 Expired (56,867 ) 2.00 (919 ) 603.89 Outstanding at March 31, 2019 4,071,579 $ 1.59 5,951,130 $ 3.29 At March 31, 2019, 3,346,375 $1.70 8.72 4,750,221 three March 31, 2019 March 31, 2018 $263,600 $226,387, $130,839 20 The following summarizes the status of options and warrants outstanding at March 31, 2019: Range of Prices Shares Weighted Remaining Life Options $ 0.619 524,958 9.77 $ 0.75 33,335 10.00 $ 0.82 60,000 9.67 $ 0.849 3,534 9.80 $ 0.90 30,000 9.92 $ 0.91 10,000 9.05 $ 0.965 3,000 9.13 $ 0.97 191,753 8.77 $ 1.01 149,110 8.88 $ 1.06 23,585 9.51 $ 1.10 86,958 9.22 $ 1.125 69,250 4.92 $ 1.13 195,931 9.31 $ 1.15 21,740 9.34 $ 1.16 66,451 9.35 $ 1.18 30,000 9.36 $ 1.20 41,668 9.34 $ 1.21 30,000 9.86 $ 1.35 111,112 8.96 $ 1.454 17,200 8.51 $ 1.47 2,271,476 8.24 $ 2.10 14,286 8.01 $ 2.25 293 7.41 $ 2.42 20,640 7.39 $ 2.80 57,145 7.76 $ 3.75 4,000 7.25 $ 4.125 3,636 7.51 $ 4.1975 7,147 7.47 $ 4.25 3,529 7.01 $ 5.125 3,902 7.44 $ 65.75 190 6.56 $ 73.50 1,157 6.76 $ 77.50 2,323 6.25 $ 80.25 187 6.51 $ 86.25 232 6.01 $ 131.25 81 3.44 $ 148.125 928 3.97 $ 150.00 1,760 3.38 $ 162.50 123 5.76 $ 206.25 121 5.51 $ 248.4375 121 4.29 $ 262.50 77 4.26 $ 281.25 529 3.80 $ 318.75 3 4.11 $ 346.875 72 5.01 $ 431.25 306 4.94 $ 506.25 188 4.76 $ 596.25 42 4.50 4,071,579 Warrants $ 0.70 754,642 4.78 $ 0.836 221,292 4.67 $ 1.00 2,495,811 4.34 $ 1.07 697,946 3.60 $ 1.155 1,071,776 4.50 $ 1.188 138,889 4.78 $ 1.3125 86,086 4.51 $ 2.25 385,000 2.82 $ 123.75 94,084 1.42 $ 243.75 2,529 0.35 $ 309.375 2,850 0.86 $ 309.50 223 0.60 5,951,130 Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of March 31, 2019 Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,500 148.13 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 100,294 2.25 – 5.13 2017 2,427,320 1.01 – 2.10 2018 1,076,358 0.62 – 1.35 2019 459,169 0.62 – 1.13 Total 4,071,579 $0.62 – $596.25 Warrants: Year Shares Price 2014 5,536 $243.75 – $309.50 2015 94,151 0.00 – 243.75 2016 252,333 1.00 2017 1,082,946 1.07 – 2.25 2018 2,190,758 0.84 – 1.155 2019 2,325,406 0.704 – 1.19 Total 5,951,130 $0.00 – $309.50

Note 5 - Notes Receivable

Note 5 - Notes Receivable	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Financing Receivables [Text Block]	NOTE 5 The Company has a secured promissory note receivable from CytoBioscience notes for $1,112,524, 8% February 28, 2020. 2019, April 2019. not As of December 31, 2018, $1,165,013, $39,092, January February 2019, $305,000. March 2019, $420,000 $250,000 April 2019. $2,140,013 $1,190,967 2. no 10.

Note 6 - Convertible Debt and D

Note 6 - Convertible Debt and Derivative Liability	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Convertible Debt and Derivative Liability [Text Block]	NOTE 6 Effective September 28, 2018, two $2,297,727 one second $500,000 not second 650,000 1,071,776 $1.155 six fifth The bridge loan accrues interest at a rate of 8% twelve September 28, 2019. $1.00 70% 20 may 2,678,328 Management has concluded the conversion feature is an embedded derivative that is required to be bifurcated and separately presented as a liability on the balance sheet. The embedded derivative’s value was determined using 70% 20 September 2018 $645,008. $19,408 three March 31, 2019. March 31, 2019 $292,153. The Company accounted for the warrants by deriving the Black-Scholes value ascertained with a discount rate of 2.94% five 59% .5361 $574,631. Effective February 7, 2019, $344,659 $2,642,387. 166,667 $0.01 $158,350, In March 2019, one $90,000 159,854 two $93,826. The value of the embedded derivative from the bridge loan as well as the derivative included in the note payable agreements with the Company’s CEO (See – Note 9 3 1. three March 31, 2019. Derivative Liability 2018 Derivative Loss Recognized to Adjustments to Derivative Liability 2019 $ 272,745 69,722 19,408 8,665 $ 353,210

Note 7 - Loss Per Share

Note 7 - Loss Per Share	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Earnings Per Share [Text Block]	NOTE 7 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended March 31, 2019 2018 Numerator Net loss available in basic and diluted calculation $ (3,293,184 ) $ (1,760,022 ) Comprehensive loss (3,293,184 ) (1,760,022 ) Denominator: Weighted average common shares outstanding-basic 15,731,517 11,383,217 Effect of diluted stock options warrants and preferred stock (1) - - Weighted average common shares outstanding-basic and diluted 15,731,517 11,383,217 Loss per common share-basic and diluted $ (0.21 ) $ (0.15 ) ( 1 March 31, 2019 March 31, 2018 10,022,709 5,950,630, March 31, 2019 5,047,700. March 31, 2019 March 31, 2018 79,246.

Note 8 - Leases

Note 8 - Leases	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	Note 8 The Company’s corporate offices are located at 2915 900, 55121. November 22, 2017, second January 28, 2013. three February 1, 2018 January 31, 2021. 5,773 2,945 2,828 Skyline Medical Europe’s offices are located at 9 1380 April 24, 2018 June 15, 2018. 2,000 750 1,250 June 14, 2027. 3,000 Lease expense was $29,212 $17,244 three March 31, 2019 March 31, 2018, The following table summarizes other information related to our operating leases: March 31, 2019 Weighted average remaining lease term – operating leases in years 7.02 Weighted average discount rate – operating leases 8 % The Company’s rent obligation for the next five 2019 $ 60,060 2020 82,320 2021 43,320 2022 40,320 2023 40,320 2024 and thereafter 161,280 Total lease payments 427,620 Less interest 93,676 Present value of lease liabilities $ 333,944

Note 9 - Related Party Transact

Note 9 - Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	NOTE 9 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. The Company and GLG have a partnership agreement with Helomics for the purpose of bringing together their proprietary technologies to build out personalized medicine platform for the diagnosis and treatment of women’s cancer. There has been no In April 2018, one six $12,000 240,000 2012 not six October 2018. April 2018 May 1, 2019, one three $13,500 On November 30, 2018, $370,000 221,292 $0.836 January 8, 2019, $950,000 $1,320,000 second 742,188 $0.704. sixth fifth January 8, 2019, 78,125 $50,000, $0.64 February 6, 2019, $300,000 $1,620,000 third 138,889 $1.188 February 1, 2019 first second third 1 one 1/2% 2 $69,722. 12,454 February March 2019, $8,665. March 31, 2019, $61,057.

Note 10 - Subsequent Events

Note 10 - Subsequent Events	3 Months Ended
	Mar. 31, 2019
Notes to Financial Statements
Subsequent Events [Text Block]	NOTE 10 On April 4, 2019, The consideration for the remaining 75% $7,822,632 4.0 $2,993,200 3.5 $2,619,050 $2,210,382 25% 2 zero 25% 75% $2,607,544. not 8,637,323 14,245,063 900,000 not On May 9, 2019, $75,000 8% 60

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Nature of Operations and Continuance of Operations Precision Therapeutics Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of March 31, 2019, 17,360,144 $.01 two 1 2 April 2009, 510 The Company acquired 25% first 2018, April 2018 June 2018, April 4, 2019, 10. 149,000 first 2018, The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $66,401,129. not first no may The Company had cash and cash equivalents of $1,124,730 March 31, 2019 one not 3, $2.1 2019. may $5.0 Since inception to March 31, 2019, $38,970,000 $9,120,000 January 2018 $2,475,000; March 2019 $1,112,000 $1,053,000. September 2018 $1,815,000. November 2018, $370,000. February 2019, $950,000, March 2019 $300,000.
Interim Financial Statements, Policy [Policy Text Block]	Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Annual Report on Form 10 April 1, 2019. may not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Developments Accounting Policies and Estimates The presentation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. January 1, 2019, $353,007 $79,252 2016 02 not The Company leases facilities under long-term operating leases that are non-cancelable and expire on various dates. At the lease commencement date, lease ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term, which includes all fixed obligations arising from the lease contract. If an interest rate is not See Note 8
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the net realizable value, with cost determined on a first first March 31, December 31, Finished goods $ 88,849 $ 58,701 Raw materials 139,183 127,003 Work-In-Process 60,991 55,362 Total $ 289,023 $ 241,066
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3 The Company’s fixed assets consist of the following: March 31, December 31, Computers and office equipment $ 205,758 $ 204,903 Leasehold improvements 140,114 140,114 Manufacturing tooling 108,955 108,955 Demo equipment 74,529 85,246 Total 529,356 539,218 Less: Accumulated depreciation 380,647 358,765 Total Fixed Assets, Net $ 148,709 $ 180,453 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $21,882 three March 31, 2019 $14,496 three March 31, 2018.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Intangible Assets Intangible assets consist of trademarks, patent costs and license fees. Amortization expense was $17,644 three March 31, 2019 $3,671 three March 31, 2018. The Company reviews identifiable intangible assets for impairment in accordance with ASC 360 Intangibles — Goodwill and Other , whenever events or changes in circumstances indicate the carrying amount may not may not not
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2015
Offering Costs [Policy Text Block]	Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one
Segment Reporting, Policy [Policy Text Block]	Segments The Company has two three March 31, 2019 Domestic International Totals Revenue $ 219,660 $ 35,581 $ 255,241 Segment Loss $ (887,831 ) $ (84,569 ) $ (972,400 ) Reconciliation of Segment Loss Description Amounts Domestic loss $ 887,831 International loss 84,569 Corporate losses 2,320,784 Total $ 3,293,184
Risks and Uncertainties Policy [Policy Text Block]	Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, December 31, Finished goods $ 88,849 $ 58,701 Raw materials 139,183 127,003 Work-In-Process 60,991 55,362 Total $ 289,023 $ 241,066
Property Plant and Equipment Useful Life [Table Text Block]	Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3
Property, Plant and Equipment [Table Text Block]	March 31, December 31, Computers and office equipment $ 205,758 $ 204,903 Leasehold improvements 140,114 140,114 Manufacturing tooling 108,955 108,955 Demo equipment 74,529 85,246 Total 529,356 539,218 Less: Accumulated depreciation 380,647 358,765 Total Fixed Assets, Net $ 148,709 $ 180,453
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Domestic International Totals Revenue $ 219,660 $ 35,581 $ 255,241 Segment Loss $ (887,831 ) $ (84,569 ) $ (972,400 ) Description Amounts Domestic loss $ 887,831 International loss 84,569 Corporate losses 2,320,784 Total $ 3,293,184

Note 2 - Equity Method Invest_2

Note 2 - Equity Method Investment (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Equity Method Investments [Table Text Block]	For the three Months Ended March 31, 2019 Revenue $ 45,835 Gross margin $ 7,348 Net loss from continuing operations $ (1,555,542 ) Net loss to investee $ (1,166,656 ) 1

Note 4 - Stockholders' Equity_2

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Share-based Payment Arrangement, Activity [Table Text Block]	Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 1,098,858 1.01 2,336,154 1.07 Expired (194,564 ) 2.00 (10,706 ) 199.55 Exercised - - (650,062 ) 1.00 Outstanding at December 31, 2018 3,669,277 $ 1.70 3,626,643 $ 4.17 Issued 459,169 0.73 2,325,406 0.92 Expired (56,867 ) 2.00 (919 ) 603.89 Outstanding at March 31, 2019 4,071,579 $ 1.59 5,951,130 $ 3.29
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block]	Range of Prices Shares Weighted Remaining Life Options $ 0.619 524,958 9.77 $ 0.75 33,335 10.00 $ 0.82 60,000 9.67 $ 0.849 3,534 9.80 $ 0.90 30,000 9.92 $ 0.91 10,000 9.05 $ 0.965 3,000 9.13 $ 0.97 191,753 8.77 $ 1.01 149,110 8.88 $ 1.06 23,585 9.51 $ 1.10 86,958 9.22 $ 1.125 69,250 4.92 $ 1.13 195,931 9.31 $ 1.15 21,740 9.34 $ 1.16 66,451 9.35 $ 1.18 30,000 9.36 $ 1.20 41,668 9.34 $ 1.21 30,000 9.86 $ 1.35 111,112 8.96 $ 1.454 17,200 8.51 $ 1.47 2,271,476 8.24 $ 2.10 14,286 8.01 $ 2.25 293 7.41 $ 2.42 20,640 7.39 $ 2.80 57,145 7.76 $ 3.75 4,000 7.25 $ 4.125 3,636 7.51 $ 4.1975 7,147 7.47 $ 4.25 3,529 7.01 $ 5.125 3,902 7.44 $ 65.75 190 6.56 $ 73.50 1,157 6.76 $ 77.50 2,323 6.25 $ 80.25 187 6.51 $ 86.25 232 6.01 $ 131.25 81 3.44 $ 148.125 928 3.97 $ 150.00 1,760 3.38 $ 162.50 123 5.76 $ 206.25 121 5.51 $ 248.4375 121 4.29 $ 262.50 77 4.26 $ 281.25 529 3.80 $ 318.75 3 4.11 $ 346.875 72 5.01 $ 431.25 306 4.94 $ 506.25 188 4.76 $ 596.25 42 4.50 4,071,579 Warrants $ 0.70 754,642 4.78 $ 0.836 221,292 4.67 $ 1.00 2,495,811 4.34 $ 1.07 697,946 3.60 $ 1.155 1,071,776 4.50 $ 1.188 138,889 4.78 $ 1.3125 86,086 4.51 $ 2.25 385,000 2.82 $ 123.75 94,084 1.42 $ 243.75 2,529 0.35 $ 309.375 2,850 0.86 $ 309.50 223 0.60 5,951,130
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,500 148.13 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 100,294 2.25 – 5.13 2017 2,427,320 1.01 – 2.10 2018 1,076,358 0.62 – 1.35 2019 459,169 0.62 – 1.13 Total 4,071,579 $0.62 – $596.25 Warrants: Year Shares Price 2014 5,536 $243.75 – $309.50 2015 94,151 0.00 – 243.75 2016 252,333 1.00 2017 1,082,946 1.07 – 2.25 2018 2,190,758 0.84 – 1.155 2019 2,325,406 0.704 – 1.19 Total 5,951,130 $0.00 – $309.50

Note 6 - Convertible Debt and_2

Note 6 - Convertible Debt and Derivative Liability (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Derivative Liabilities at Fair Value [Table Text Block]	Derivative Liability 2018 Derivative Loss Recognized to Adjustments to Derivative Liability 2019 $ 272,745 69,722 19,408 8,665 $ 353,210

Note 7 - Loss Per Share (Tables

Note 7 - Loss Per Share (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, 2019 2018 Numerator Net loss available in basic and diluted calculation $ (3,293,184 ) $ (1,760,022 ) Comprehensive loss (3,293,184 ) (1,760,022 ) Denominator: Weighted average common shares outstanding-basic 15,731,517 11,383,217 Effect of diluted stock options warrants and preferred stock (1) - - Weighted average common shares outstanding-basic and diluted 15,731,517 11,383,217 Loss per common share-basic and diluted $ (0.21 ) $ (0.15 )

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	3 Months Ended
	Mar. 31, 2019
Notes Tables
Lease, Cost [Table Text Block]	March 31, 2019 Weighted average remaining lease term – operating leases in years 7.02 Weighted average discount rate – operating leases 8 %
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2019 $ 60,060 2020 82,320 2021 43,320 2022 40,320 2023 40,320 2024 and thereafter 161,280 Total lease payments 427,620 Less interest 93,676 Present value of lease liabilities $ 333,944

Note 1 - Summary of Significa_3

Note 1 - Summary of Significant Accounting Policies (Details Textual)	Feb. 06, 2019USD ($)	Jan. 08, 2019USD ($)	Nov. 30, 2018USD ($)	Mar. 31, 2019USD ($)$ / sharesshares	Feb. 28, 2019USD ($)	Nov. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Jan. 31, 2018USD ($)	Mar. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2018USD ($)	Mar. 22, 2019$ / shares	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 28, 2017$ / shares
Common Stock, Shares, Outstanding, Ending Balance | shares				17,360,144					17,360,144				14,091,748
Common Stock, Par or Stated Value Per Share | $ / shares				$ 0.01					$ 0.01		$ 0.01		$ 0.01	$ 0.01
Retained Earnings (Accumulated Deficit), Ending Balance				$ (66,401,129)					$ (66,401,129)				$ (63,107,945)
Cash and Cash Equivalents, at Carrying Value, Ending Balance				1,124,730					1,124,730				162,152
Stockholders' Equity, Period Increase (Decrease), Total									38,970,000
Debt Instrument, Increase (Decrease), Net, Total									9,120,000
Operating Lease, Right-of-Use Asset				333,944					333,944
Operating Lease, Liability, Current				78,819					78,819
Depreciation, Total									21,882	$ 14,496
Amortization of Intangible Assets, Total									17,644	$ 3,671
Income Tax Expense (Benefit), Total									0
Unrecognized Tax Benefits, Ending Balance				0					0
Liability for Uncertainty in Income Taxes, Current				0					$ 0
Open Tax Year									2015 2016 2017 2018
Number of Operating Segments									2
Operating Lease, Liability, Total				333,944					$ 333,944
Accounting Standards Update 2016-02 [Member]
Operating Lease, Right-of-Use Asset												$ 353,007
Operating Lease, Liability, Current												79,252
Operating Lease, Liability, Total												$ 353,007
Chief Executive Officer [Member]
Proceeds from Related Party Debt	$ 300,000	$ 950,000	$ 370,000	300,000	$ 950,000	$ 370,000
Convertible Promissory Note [Member]
Proceeds from Debt, Net of Issuance Costs							$ 1,815,000
S-3 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total									2,100,000
Issuance or Sale of Equity, Potentially Issuable				5,000,000					$ 5,000,000
The 2018 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total								$ 2,475,000
First S-3 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total				1,112,000
Second S-3 Public Offering [Member]
Proceeds from Issuance or Sale of Equity, Total				$ 1,053,000
Helomics Holding Corp. [Member]
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage										25.00%

Note 1 - Summary of Significa_4

Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Finished goods	$ 88,849	$ 58,701
Raw materials	139,183	127,003
Work-In-Process	60,991	55,362
Total	$ 289,023	$ 241,066

Note 1 - Summary of Significa_5

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details)	3 Months Ended
	Mar. 31, 2019
Leasehold Improvements [Member]
Property, plant, and equipment, useful life (Year)	3 years
Demo Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	3 years
Minimum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant, and equipment, useful life (Year)	7 years
Maximum [Member] | Manufacturing Tooling [Member]
Property, plant, and equipment, useful life (Year)	7 years

Note 1 - Summary of Significa_6

Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Property, Plant, and Equipment Gross	$ 529,356	$ 539,218
Less: Accumulated depreciation	380,647	358,765
Total Fixed Assets, Net	148,709	180,453
Office Equipment [Member]
Property, Plant, and Equipment Gross	205,758	204,903
Leasehold Improvements [Member]
Property, Plant, and Equipment Gross	140,114	140,114
Manufacturing Tooling [Member]
Property, Plant, and Equipment Gross	108,955	108,955
Demo Equipment [Member]
Property, Plant, and Equipment Gross	$ 74,529	$ 85,246

Note 1 - Summary of Significa_7

Note 1 - Summary of Significant Accounting Policies - Segments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue	$ 255,241	$ 411,593
Segment Loss	(3,293,184)	(1,760,022)
Segment Loss	3,293,184	$ 1,760,022
Domestic [Member]
Revenue	219,660
Segment Loss	(887,831)
Segment Loss	887,831
International [Member]
Revenue	35,581
Segment Loss	(84,569)
Segment Loss	84,569
Domestic and International Segments [Member]
Segment Loss	(972,400)
Segment Loss	972,400
Corporate Segment [Member]
Segment Loss	(2,320,784)
Segment Loss	$ 2,320,784

Note 2 - Equity Method Invest_3

Note 2 - Equity Method Investment (Details Textual)	Sep. 30, 2018
Helomics Holding Corp. [Member]
Equity Method Investment, Ownership Percentage	75.00%

Note 2 - Equity Method Invest_4

Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details)	3 Months Ended
	Mar. 31, 2019USD ($)
Revenue	$ 45,835
Gross margin	7,348
Net loss from continuing operations	(1,555,542)
Net loss to investee	$ (1,166,656)	[1]
[1]	The loss to investee was calculated at 75% for the three-month period at the current equity investment percentage owned by the Company.

Note 3 - Revenue Recognition (D

Note 3 - Revenue Recognition (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice	1 year
Standard Product Warranty, Term	1 year
Accounts Receivable, after Allowance for Credit Loss, Current, Total	$ 173,443	$ 232,602
Contract with Customer, Liability, Current	$ 20,929	$ 23,065
Maintenance [Member]
Revenue, Performance Obligation, Timing	1 year
Minimum [Member]
Standard Payment Term for Customers	30 days
Maximum [Member]
Standard Payment Term for Customers	60 days

Note 4 - Stockholders' Equity_3

Note 4 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Mar. 22, 2019	Dec. 28, 2017	Jan. 29, 2017
Common Stock, Shares Authorized	100,000,000	100,000,000		100,000,000	100,000,000	50,000,000	24,000,000
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01		$ 0.01	$ 0.01	$ 0.01
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		79.80%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number	3,346,375	3,346,375
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price	$ 1.70	$ 1.70
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term		8 years 262 days
Class of Warrant or Right Number of Warrants Vested and Exercisable	4,750,221	4,750,221
Share-based Payment Arrangement, Expense		$ 263,600	$ 226,387
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 130,839	$ 130,839
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.73		$ 1.01
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition		1 year 240 days
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 309.50	$ 309.50
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.76%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.7644
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		2.41%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.4112
Amended and Restated 2012 Stock Incentive Plan [Member]
Common Stock, Shares Authorized					10,000,000
Equity Incentive Plan [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period		3 years
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		10 years
Equity Incentive Plan [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		3 years
Warrants Issued With First 2019 Registered Direct Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	692,500	692,500
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0.5	0.5
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1	$ 1
The First 2019 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues	1,385,000
Share Per Each Unit	1	1
Shares Issued, Price Per Share	$ 0.90	$ 0.90
Proceeds from Issuance or Sale of Equity, Total		$ 1,246,608
Right to Purchase Units, Assigned to Underwriters	69,250	69,250
Units, Exercise Price Percent of Offering Price	125.00%	125.00%
Class of Warrant or Right, Issued per Unit	1.125
The Second 2019 Registered Direct Offering [Member]
Stock Issued During Period, Shares, New Issues	1,478,750
Share Per Each Unit	1	1
Shares Issued, Price Per Share	$ 0.80	$ 0.80
Proceeds from Issuance or Sale of Equity, Total		$ 1,183,101
Right to Purchase Units, Assigned to Underwriters	73,937	73,937
Units, Exercise Price Percent of Offering Price	125.00%	125.00%
Class of Warrant or Right, Issued per Unit	1
Warrants Issued With Second 2019 Registered Direct Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	739,377	739,377
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	0.5	0.5
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1	$ 1

Note 4 - Stockholders' Equity,

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Number of Shares Outstanding (in shares)	4,071,579
Warrant [Member]
Number of Shares Outstanding (in shares)	3,626,643	1,951,257
Average Exercise Price Outstanding (in dollars per share)	$ 4.17	$ 23.74
Number of Shares Issued (in shares)	2,325,406	2,336,154
Average Exercise Price Issued (in dollars per share)	$ 0.92	$ 1.07
Number of Shares Expired (in shares)	(919)	(10,706)
Average Exercise Price Expired (in dollars per share)	$ 603.89	$ 199.55
Number of Shares Exercised (in shares)		(650,062)
Average Exercise Price Exercised (in dollars per share)		$ 1
Number of Shares Outstanding (in shares)	5,951,130	3,626,643
Average Exercise Price Outstanding (in dollars per share)	$ 3.29	$ 4.17
Share-based Payment Arrangement, Option [Member]
Number of Shares Outstanding (in shares)	3,669,277	2,764,983
Average Exercise Price Outstanding (in dollars per share)	$ 1.70	$ 2
Number of Shares Issued (in shares)	459,169	1,098,858
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 0.73	$ 1.01
Number of Shares Expired (in shares)	(56,867)	(194,564)
Average Exercise Price Expired (in dollars per share)	$ 2	$ 2
Number of Shares Exercised (in shares)
Average Exercise Price Exercised (in dollars per share)
Number of Shares Outstanding (in shares)	4,071,579	3,669,277
Average Exercise Price Outstanding (in dollars per share)	$ 1.59	$ 1.70

Note 4 - Stockholders' Equity_4

Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Shares, options (in shares)	4,071,579
Weighted average remaining life, options (Year)
Shares, warrants (in shares)	5,951,130
Weighted average remaining life, warrants (Year)
Warrant One [Member]
Warrant exercises, price per share (in dollars per share) | $ / shares	$ 0.70
Shares, warrants (in shares)	754,642
Weighted average remaining life, warrants (Year)	4 years 284 days
Warrant Two [Member]
Warrant exercises, price per share (in dollars per share) | $ / shares	$ 0.836
Shares, warrants (in shares)	221,292
Weighted average remaining life, warrants (Year)	4 years 244 days
Warrant Three [Member]
Warrant exercises, price per share (in dollars per share) | $ / shares	$ 1
Shares, warrants (in shares)	2,495,811
Weighted average remaining life, warrants (Year)	4 years 124 days
Warrant Four [Member]
Warrant exercises, price per share (in dollars per share) | $ / shares	$ 1.07
Shares, warrants (in shares)	697,946
Weighted average remaining life, warrants (Year)	3 years 219 days
Warrant Five [Member]
Warrant exercises, price per share (in dollars per share) | $ / shares	$ 1.155
Shares, warrants (in shares)	1,071,776
Weighted average remaining life, warrants (Year)	4 years 182 days
Warrant Six [Member]
Warrant exercises, price per share (in dollars per share) | $ / shares	$ 1.188
Shares, warrants (in shares)	138,889
Weighted average remaining life, warrants (Year)	4 years 284 days
Warrant Seven [Member]
Warrant exercises, price per share (in dollars per share) | $ / shares	$ 1.3125
Shares, warrants (in shares)	86,086
Weighted average remaining life, warrants (Year)	4 years 186 days
Warrant Eight [Member]
Warrant exercises, price per share (in dollars per share) | $ / shares	$ 2.25
Shares, warrants (in shares)	385,000
Weighted average remaining life, warrants (Year)	2 years 299 days
Warrant Nine [Member]
Warrant exercises, price per share (in dollars per share) | $ / shares	$ 123.75
Shares, warrants (in shares)	94,084
Weighted average remaining life, warrants (Year)	1 year 153 days
Warrant Ten [Member]
Warrant exercises, price per share (in dollars per share) | $ / shares	$ 243.75
Shares, warrants (in shares)	2,529
Weighted average remaining life, warrants (Year)	127 days
Warrant Eleven [Member]
Warrant exercises, price per share (in dollars per share) | $ / shares	$ 309.375
Shares, warrants (in shares)	2,850
Weighted average remaining life, warrants (Year)	313 days
Warrant Twelve [Member]
Warrant exercises, price per share (in dollars per share) | $ / shares	$ 309.50
Shares, warrants (in shares)	223
Weighted average remaining life, warrants (Year)	219 days
Stock Options One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 0.619
Shares, options (in shares)	524,958
Weighted average remaining life, options (Year)	9 years 281 days
Stock Options Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 0.75
Shares, options (in shares)	33,335
Weighted average remaining life, options (Year)	10 years
Stock Options Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 0.82
Shares, options (in shares)	60,000
Weighted average remaining life, options (Year)	9 years 244 days
Stock Options Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 0.849
Shares, options (in shares)	3,534
Weighted average remaining life, options (Year)	9 years 292 days
Stock Options Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 0.90
Shares, options (in shares)	30,000
Weighted average remaining life, options (Year)	9 years 335 days
Stock Options Six [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 0.91
Shares, options (in shares)	10,000
Weighted average remaining life, options (Year)	9 years 18 days
Stock Options Seven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 0.965
Shares, options (in shares)	3,000
Weighted average remaining life, options (Year)	9 years 47 days
Stock Options Eight [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 0.97
Shares, options (in shares)	191,753
Weighted average remaining life, options (Year)	8 years 281 days
Stock Options Nine [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.01
Shares, options (in shares)	149,110
Weighted average remaining life, options (Year)	8 years 321 days
Stock Options Ten [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.06
Shares, options (in shares)	23,585
Weighted average remaining life, options (Year)	9 years 186 days
Stock Options Eleven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.10
Shares, options (in shares)	86,958
Weighted average remaining life, options (Year)	9 years 80 days
Stock Options Twelve [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.125
Shares, options (in shares)	69,250
Weighted average remaining life, options (Year)	4 years 335 days
Stock Options Thirteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.13
Shares, options (in shares)	195,931
Weighted average remaining life, options (Year)	9 years 113 days
Stock Options Fourteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.15
Shares, options (in shares)	21,740
Weighted average remaining life, options (Year)	9 years 124 days
Stock Options Fifteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.16
Shares, options (in shares)	66,451
Weighted average remaining life, options (Year)	9 years 127 days
Stock Options Sixteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.18
Shares, options (in shares)	30,000
Weighted average remaining life, options (Year)	9 years 131 days
Stock Options Seventeen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.20
Shares, options (in shares)	41,668
Weighted average remaining life, options (Year)	9 years 124 days
Stock Options Eighteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.21
Shares, options (in shares)	30,000
Weighted average remaining life, options (Year)	9 years 313 days
Stock Options Nineteen [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.35
Shares, options (in shares)	111,112
Weighted average remaining life, options (Year)	8 years 350 days
Stock Options Twenty [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.454
Shares, options (in shares)	17,200
Weighted average remaining life, options (Year)	8 years 186 days
Stock Options Twenty One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 1.47
Shares, options (in shares)	2,271,476
Weighted average remaining life, options (Year)	8 years 87 days
Stock Options Twenty Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.10
Shares, options (in shares)	14,286
Weighted average remaining life, options (Year)	8 years 3 days
Stock Options Twenty Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.25
Shares, options (in shares)	293
Weighted average remaining life, options (Year)	7 years 149 days
Stock Options Twenty Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.42
Shares, options (in shares)	20,640
Weighted average remaining life, options (Year)	7 years 142 days
Stock Options Twenty Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 2.80
Shares, options (in shares)	57,145
Weighted average remaining life, options (Year)	7 years 277 days
Stock Options Twenty Six [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 3.75
Shares, options (in shares)	4,000
Weighted average remaining life, options (Year)	7 years 91 days
Stock Options Twenty Seven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.125
Shares, options (in shares)	3,636
Weighted average remaining life, options (Year)	7 years 186 days
Stock Options Twenty Eight [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.1975
Shares, options (in shares)	7,147
Weighted average remaining life, options (Year)	7 years 171 days
Stock Options Twenty Nine [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 4.25
Shares, options (in shares)	3,529
Weighted average remaining life, options (Year)	7 years 3 days
Stock Options Thirty [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 5.125
Shares, options (in shares)	3,902
Weighted average remaining life, options (Year)	7 years 160 days
Stock Options Thirty-One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 65.75
Shares, options (in shares)	190
Weighted average remaining life, options (Year)	6 years 204 days
Stock Options Thirty-Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 73.50
Shares, options (in shares)	1,157
Weighted average remaining life, options (Year)	6 years 277 days
Stock Options Thirty-Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 77.50
Shares, options (in shares)	2,323
Weighted average remaining life, options (Year)	6 years 91 days
Stock Options Thirty-Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 80.25
Shares, options (in shares)	187
Weighted average remaining life, options (Year)	6 years 186 days
Stock Options Thirty-Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 86.25
Shares, options (in shares)	232
Weighted average remaining life, options (Year)	6 years 3 days
Stock Options Thirty-Six [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 131.25
Shares, options (in shares)	81
Weighted average remaining life, options (Year)	3 years 160 days
Stock Options Thirty-Seven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 148.125
Shares, options (in shares)	928
Weighted average remaining life, options (Year)	3 years 354 days
Stock Options Thirty-Eight [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 150
Shares, options (in shares)	1,760
Weighted average remaining life, options (Year)	3 years 138 days
Stock Options Thirty-Nine [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 162.50
Shares, options (in shares)	123
Weighted average remaining life, options (Year)	5 years 277 days
Stock Options Forty [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 206.25
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	5 years 186 days
Stock Options Forty-One [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 248.4375
Shares, options (in shares)	121
Weighted average remaining life, options (Year)	4 years 105 days
Stock Options Forty-Two [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 262.50
Shares, options (in shares)	77
Weighted average remaining life, options (Year)	4 years 94 days
Stock Options Forty-Three [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 281.25
Shares, options (in shares)	529
Weighted average remaining life, options (Year)	3 years 292 days
Stock Options Forty-Four [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 318.75
Shares, options (in shares)	3
Weighted average remaining life, options (Year)	4 years 40 days
Stock Options Forty-Five [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 346.875
Shares, options (in shares)	72
Weighted average remaining life, options (Year)	5 years 3 days
Stock Options Fortysix [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 431.25
Shares, options (in shares)	306
Weighted average remaining life, options (Year)	4 years 343 days
Stock Options Forty-seven [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 506.25
Shares, options (in shares)	188
Weighted average remaining life, options (Year)	4 years 277 days
Stock Options Forty-eight [Member]
Range of exercise prices, options (in dollars per share) | $ / shares	$ 596.25
Shares, options (in shares)	42
Weighted average remaining life, options (Year)	4 years 182 days

Note 4 - Stockholders' Equity_5

Note 4 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details)	Mar. 31, 2019$ / sharesshares
Shares, options (in shares) | shares	4,071,579
Shares, warrants (in shares) | shares	5,951,130
Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 0.62
Warrant exercises, price per share (in dollars per share)	0
Maximum [Member]
Range of exercise prices, options (in dollars per share)	596.25
Warrant exercises, price per share (in dollars per share)	$ 309.50
Warrants 2014 [Member]
Shares, warrants (in shares) | shares	5,536
Warrants 2014 [Member] | Minimum [Member]
Warrant exercises, price per share (in dollars per share)	$ 243.75
Warrants 2014 [Member] | Maximum [Member]
Warrant exercises, price per share (in dollars per share)	$ 309.50
Warrants 2015 [Member]
Shares, warrants (in shares) | shares	94,151
Warrants 2015 [Member] | Minimum [Member]
Warrant exercises, price per share (in dollars per share)	$ 0
Warrants 2015 [Member] | Maximum [Member]
Warrant exercises, price per share (in dollars per share)	$ 243.75
Warrants 2016 [Member]
Shares, warrants (in shares) | shares	252,333
Warrant exercises, price per share (in dollars per share)	$ 1
Warrants 2017 [Member]
Shares, warrants (in shares) | shares	1,082,946
Warrants 2017 [Member] | Minimum [Member]
Warrant exercises, price per share (in dollars per share)	$ 1.07
Warrants 2017 [Member] | Maximum [Member]
Warrant exercises, price per share (in dollars per share)	$ 2.25
Warrants 2018 [Member]
Shares, warrants (in shares) | shares	2,190,758
Warrants 2018 [Member] | Minimum [Member]
Warrant exercises, price per share (in dollars per share)	$ 0.84
Warrants 2018 [Member] | Maximum [Member]
Warrant exercises, price per share (in dollars per share)	$ 1.155
Warrants 2019 [Member]
Shares, warrants (in shares) | shares	2,325,406
Warrants 2019 [Member] | Minimum [Member]
Warrant exercises, price per share (in dollars per share)	$ 0.704
Warrants 2019 [Member] | Maximum [Member]
Warrant exercises, price per share (in dollars per share)	$ 1.19
Stock Options 2011 [Member]
Shares, options (in shares) | shares	173
Range of exercise prices, options (in dollars per share)	$ 281.25
Stock Options 2012 [Member]
Shares, options (in shares) | shares	1,841
Stock Options 2012 [Member] | Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 131.25
Stock Options 2012 [Member] | Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 150
Stock Options 2013 [Member]
Shares, options (in shares) | shares	1,500
Stock Options 2013 [Member] | Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 148.13
Stock Options 2013 [Member] | Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 596.25
Stock Options 2014 [Member]
Shares, options (in shares) | shares	836
Stock Options 2014 [Member] | Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 162.50
Stock Options 2014 [Member] | Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 431.25
Stock Options 2015 [Member]
Shares, options (in shares) | shares	4,088
Stock Options 2015 [Member] | Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 65.75
Stock Options 2015 [Member] | Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 86.25
Stock Options 2016 [Member]
Shares, options (in shares) | shares	100,294
Stock Options 2016 [Member] | Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 2.25
Stock Options 2016 [Member] | Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 5.13
Stock Options 2017 [Member]
Shares, options (in shares) | shares	2,427,320
Stock Options 2017 [Member] | Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 1.01
Stock Options 2017 [Member] | Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 2.10
Stock Options 2018 [Member]
Shares, options (in shares) | shares	1,076,358
Stock Options 2018 [Member] | Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 0.62
Stock Options 2018 [Member] | Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 1.35
Stock Options 2019 [Member]
Shares, options (in shares) | shares	459,169
Stock Options 2019 [Member] | Minimum [Member]
Range of exercise prices, options (in dollars per share)	$ 0.62
Stock Options 2019 [Member] | Maximum [Member]
Range of exercise prices, options (in dollars per share)	$ 1.13

Note 5 - Notes Receivable (Deta

Note 5 - Notes Receivable (Details Textual) - USD ($)	1 Months Ended		2 Months Ended
	Apr. 30, 2019	Mar. 31, 2019	Feb. 28, 2019	Dec. 31, 2018	Mar. 31, 2018
Shelf Registration [Member] | Subsequent Event [Member]
Financing Receivable, before Allowance for Credit Loss, Total	$ 2,140,013
Proceeds from Issuance or Sale of Equity, Total	250,000
CytoBioscience [Member] | Promissory Notes Receivable [Member]
Financing Receivable, after Allowance for Credit Loss, Total					$ 1,112,524
Notes Receivable, Interest Rate, Stated Percentage					8.00%
Helomics Holding Corp. [Member]
Financing Receivable, before Allowance for Credit Loss, Total				$ 1,165,013
Interest Receivable				$ 39,092
Payments to Acquire Notes Receivable			$ 305,000
Helomics Holding Corp. [Member] | Subsequent Event [Member]
Increase (Decrease) in Notes Payable, Current, Total	$ (1,190,967)
Helomics Holding Corp. [Member] | Shelf Registration [Member]
Payments to Acquire Notes Receivable		$ 420,000

Note 6 - Convertible Debt and_3

Note 6 - Convertible Debt and Derivative Liability (Details Textual)	Mar. 31, 2019USD ($)yr$ / shares	Feb. 07, 2019USD ($)$ / sharesshares	Oct. 26, 2018	Oct. 03, 2018$ / sharesshares	Mar. 31, 2019USD ($)yr$ / sharesshares	Mar. 31, 2019USD ($)yr$ / shares	Mar. 31, 2018USD ($)	Mar. 22, 2019$ / shares	Dec. 31, 2018$ / shares	Sep. 30, 2018USD ($)	Sep. 28, 2018USD ($)	Dec. 28, 2017$ / shares
Stock Issued During Period, Shares, Inducement for Bridge Loan | shares				650,000
Debt Instrument, Increase (Decrease), Net, Total						$ 9,120,000
Common Stock, Par or Stated Value Per Share | $ / shares	$ 0.01				$ 0.01	$ 0.01		$ 0.01	$ 0.01			$ 0.01
Stock Issued During Period, Value, Forebearance for Bridge Loan						$ 158,350
Debt Conversion, Converted Instrument, Amount						90,000
Embedded Derivative Financial Instruments [Member]
Derivative Liability, Total	$ 292,153				$ 292,153	292,153				$ 645,008
Unrealized Gain (Loss) on Derivatives						$ (19,408)
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares	$ 309.50				$ 309.50	$ 309.50
Warrants in Connection with Convertible Promissory Note [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares				1,071,776
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares				$ 1.155
Class of Warrant or Right, Vesting Period			180 days
Warrants and Rights Outstanding, Term				5 years
Class of Warrant or Right, Fair Value per Warrant | $ / shares	$ 0.5361				$ 0.5361	$ 0.5361
Warrants and Rights Outstanding	$ 574,631				$ 574,631	$ 574,631
Warrants in Connection with Convertible Promissory Note [Member] | Measurement Input, Discount Rate [Member]
Warrants and Rights Outstanding, Measurement Input	0.0294				0.0294	0.0294
Warrants in Connection with Convertible Promissory Note [Member] | Measurement Input, Expected Term [Member]
Warrants and Rights Outstanding, Measurement Input | yr	5				5	5
Warrants in Connection with Convertible Promissory Note [Member] | Measurement Input, Price Volatility [Member]
Warrants and Rights Outstanding, Measurement Input	0.59				0.59	0.59
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member]
Debt Instrument, Face Amount											$ 2,297,727
Proceeds from Notes Payable, Total	$ 500,000
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Debt Instrument, Term				1 year
Debt Instrument, Convertible, Conversion Price, Percentage of Lowers Volume-weighted Average Price of Common Stock				70.00%
Debt Instrument, Convertible, Threshold Trading Days				20
Conversion Shares, Sum of Number of Conversion Shares Plus Inducement Shares | shares				2,678,328
Securities Purchase Agreements [Member] | Convertible Promissory Note [Member] | Maximum [Member]
Debt Instrument, Convertible, Conversion Price | $ / shares				$ 1
Bridge Notes [Member]
Debt Instrument, Increase (Decrease), Net, Total		$ 344,659
Long-term Debt, Total		$ 2,642,387
Stock Issued During Period, Shares, Forebearance for Bridge Loan | shares		166,667
Common Stock, Par or Stated Value Per Share | $ / shares	$ 2	$ 0.01			$ 2	$ 2
Stock Issued During Period, Value, Forebearance for Bridge Loan		$ 158,350
Debt Conversion, Converted Instrument, Amount					$ 90,000
Debt Conversion, Converted Instrument, Shares Issued | shares					159,854
Increase (Decrease) in Notes Payable, Current, Total					$ (93,826)

Note 6 - Convertible Debt and_4

Note 6 - Convertible Debt and Derivative Liability - Change in Fair Value of Derivative Liabilities (Details) - Fair Value, Inputs, Level 3 [Member]	3 Months Ended
	Mar. 31, 2019USD ($)
Balance	$ 69,722
Warrant contingent interest	19,408
Unrealized loss	8,665
Unrealized gain	$ 353,210

Note 7 - Loss Per Share (Detail

Note 7 - Loss Per Share (Details Textual) - shares	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	10,022,709	5,950,630
Convertible Debt Securities [Member]
Weighted Average Number of Shares, Contingently Issuable	5,047,700
Preferred Stock 1 [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	79,246

Note 7 - Loss Per Share - Share

Note 7 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($)		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Net loss available in basic and diluted calculation		$ (3,293,184)	$ (1,760,022)
Comprehensive loss		$ (3,293,184)	$ (1,760,022)
Weighted average common shares outstanding-basic (in shares)		15,731,517	11,383,217
Effect of diluted stock options warrants and preferred stock (1) (in shares)	[1]
Weighted average common shares outstanding-basic and diluted (in shares)		15,731,517	11,383,217
Loss per common share - basic and diluted (in dollars per share)		$ (0.21)	$ (0.15)
[1]	The number of shares underlying options and warrants outstanding as of March 31, 2019 and March 31, 2018 are 10,022,709 and 5,950,630, respectively. The number of shares underlying the convertible debt as of March 31, 2019 is 5,047,700. The number of shares underlying the preferred stock as of March 31, 2019 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants, convertible debt and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive.

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	Jun. 15, 2018EUR (€)ft²	Mar. 31, 2019USD ($)	Mar. 31, 2018USD ($)	Feb. 01, 2018ft²
Operating Leases, Rent Expense, Total | $		$ 29,212	$ 17,244
Corporate Office, Minnesota [Member]
Lessee, Operating Lease, Term of Contract				3 years
Area of Real Estate Property				5,773
Corporate Office, Minnesota [Member] | Office Space [Member]
Area of Real Estate Property				2,945
Corporate Office, Minnesota [Member] | Manufacturing Facility [Member]
Area of Real Estate Property				2,828
Skyline Medical Europe’s Offices Lease [Member]
Area of Real Estate Property	2,000
Lessee, Operating Lease, Monthly Rent | €	€ 3,000
Skyline Medical Europe’s Offices Lease [Member] | Office Space [Member]
Area of Real Estate Property	1,250
Skyline Medical Europe’s Offices Lease [Member] | Storage Space [Member]
Area of Real Estate Property	750

Note 8 - Leases - Lease Informa

Note 8 - Leases - Lease Information (Details)	Mar. 31, 2019
Weighted average remaining lease term – operating leases in years (Year)	7 years 7 days
Weighted average discount rate – operating leases	8.00%

Note 8 - Leases - Rent Obligati

Note 8 - Leases - Rent Obligation (Details)	Mar. 31, 2019USD ($)
2019	$ 60,060
2020	82,320
2021	43,320
2022	40,320
2023	40,320
2024 and thereafter	161,280
Total lease payments	427,620
Less interest	93,676
Present value of lease liabilities	$ 333,944

Note 9 - Related Party Transa_2

Note 9 - Related Party Transactions (Details Textual) - USD ($)	Feb. 06, 2019	Feb. 01, 2019	Jan. 08, 2019	Nov. 30, 2018	Mar. 31, 2019	Feb. 28, 2019	Nov. 30, 2018	Apr. 30, 2018	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Sep. 30, 2018
Proceeds from Issuance of Common Stock										$ 2,479,709	$ 2,959,509
Embedded Derivative Financial Instruments [Member]
Derivative Liability, Total					$ 292,153				$ 292,153	292,153		$ 292,153	$ 645,008
Schwartz Warrant First Tranche [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights				221,292			221,292
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 0.836			$ 0.836
Schwartz Warrant Third Tranche [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	138,889
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 1.188
Schwartz Warrant [Member]
Class of Warrant or Right, Additional Shares Increase, Percentage		0.50%
Director [Member]
Related Party Transaction, Contract Term								6 years				180 days
Related Party Transaction, Monthly Cash Payment										$ 12,000		$ 13,500
Director [Member] | Restricted Stock Units (RSUs) [Member]
Stock Issued During Period, Shares, New Issues										240,000
Chief Executive Officer [Member]
Stock Issued During Period, Shares, New Issues			78,125
Proceeds from Related Party Debt	$ 300,000		$ 950,000	$ 370,000	300,000	$ 950,000	$ 370,000
Due to Related Parties, Total			1,320,000
Proceeds from Issuance of Common Stock			$ 50,000
Shares Issued, Price Per Share			$ 0.64
Chief Executive Officer [Member] | Schwartz Note [Member]
Debt Instrument, Face Amount	$ 1,620,000
Chief Executive Officer [Member] | Schwartz Warrant Second Tranche [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			742,188
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.704
Chief Executive Officer [Member] | Schwartz Warrant [Member]
Class of Warrant or Right Issued During Period									12,454
Chief Executive Officer [Member] | Schwartz Warrant [Member] | Embedded Derivative Financial Instruments [Member]
Derivative Liability, Total				$ 69,722	$ 61,057		$ 69,722		$ 61,057	$ 61,057		$ 61,057
Derivative Liability, Change in Fair Value Due to Issuance of Warrants									$ (8,665)

Note 10 - Subsequent Events (De

Note 10 - Subsequent Events (Details Textual) - USD ($)	May 09, 2019	Apr. 04, 2019	Mar. 31, 2019	Mar. 31, 2018	Apr. 03, 2019
Proceeds from Issuance of Debt			$ 1,250,000
Subsequent Event [Member] | Loans From Dr. Schwartz [Member] | Chief Executive Officer [Member]
Proceeds from Issuance of Debt	$ 75,000
Debt Instrument, Interest Rate, Stated Percentage	8.00%
Helomics Acquisition, Inc. [Member] | Subsequent Event [Member]
Business Acquisition, Percentage of Voting Interests Acquired		75.00%			25.00%
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		8,637,323
Gain (Loss) on Extinguishment of Debt, Total		$ 2,210,382
Business Acquisition, Revaluation, Gain (Loss) on Acquisition		$ 2,607,544
Helomics Acquisition, Inc. [Member] | Subsequent Event [Member] | Warrants Issued to Holders of Helomics Notes and Warrants [Member]
Class of Warrant or Right Issued During Period		14,245,063
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 900,000
Helomics Acquisition, Inc. [Member] | Subsequent Event [Member] | Common Stock [Member]
Business Combination, Consideration Transferred, Total		$ 7,822,632
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		4,000,000
Business Combination, Merger Date Valuation		$ 2,993,200
Helomics Acquisition, Inc. [Member] | Subsequent Event [Member] | Preferred Stock [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares		3,500,000
Business Combination, Merger Date Valuation		$ 2,619,050